
- Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular trading session at $239.12. The company shares traded at $242, up 1.2 percent in the after-hours trading session.
- The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ:YMAB) lead Durg DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. Y-mAbs shares traded as high as 1.29 percent, in a range of $14.56 to $15.7 on day volume of 189.45 thousand shares, closed regular trading session at $15.55.